NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update<
07 Aug 2023

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of patients with uncontrolled or resistant hypertension

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update<
04 Aug 2023

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED
Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference<
18 Jul 2023

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

Synendos investigates the therapeutic potential of this novel mode of action and Prof. Gertsch's pioneering research forms the basis of Synendos’ approach
Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)<
18 Jul 2023

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

Trial to evaluate lorundrostat as a treatment for patients with Stage 2 to 4 chronic kidney disease

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics<
13 Jul 2023

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

SparingVision to receive equity, milestone payments, and royalties

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics<
22 Jun 2023

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics

Proceeds will be used to advance the lead program, a click-cleavable ADC targeting TAG72, into the clinic, and expand the pipeline
Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer<
20 Jun 2023

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer

Strengthening of strategic option license agreement to cover additional novel ADC targets
SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program<
20 Jun 2023

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program

Dr. Favre brings extensive experience in gene therapy, immunology and drug development
CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment<
20 Jun 2023

CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment

Investment to fund its first industrial deployment and entry into clinical trials.
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway<
14 Jun 2023

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

LAVA-1207 for the treatment of prostate cancer will continue as the lead program

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка